华彬,
Email: huabinbjh@126.com
Citation： 李波, 华彬, 陈悦. Consideration of Individualized Treatment of Breast Cancer in Age Less Than 35 Years Women. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2014, 21(5): 539-543. doi: 10.7507/1007-9424.20140131 Copy
Copyright © the editorial department of CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY of West China Medical Publisher. All rights reserved
| 1. | Han W, Kim SW, Park IA, et al.Young age:an independent risk factor for disease-free survival in women with operable breast cancer[J].BMC Cancer, 2004, 4:82. |
| 2. | Han W, Kang SY; Korean Breast Cancer Society.Relationship between age at diagnosis and outcome of premenopausal breast cancer:age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer[J].Breast Cancer Res Treat, 2010, 119(1):193-200. |
| 3. | Kim EK, Noh WC, Han W, et al.Prognostic significance of young age ( < 35 years) by subtype based on ER, PR, and HER2 status in breast cancer:a nationwide registry-based study[J].World J Surg, 2011, 35(6):1244-1253. |
| 4. | Kim IK, Park S, Hwang H, et al.Clinical significance of age at the time of diagnosis among young breast cancer patients[J].J Breast Cancer, 2011, 14(4):314-321. |
| 5. | Althuis MD, Brogan DD, Coates RJ, et al.Breast cancers among very young premenopausal women (United States)[J].Cancer Causes Control, 2003, 14(2):151-160. |
| 6. | Rodriguez AO, Chew H, Cress R, et al.Evidence of poorer survival in pregnancy-associated breast cancer[J].Obstet Gynecol, 2008, 112(1):71-78. |
| 7. | Antoniou A, Pharoah PD, Narod S, et al.Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:a combined analysis of 22 studies[J].Am J Hum Genet, 2003, 72(5):1117-1130. |
| 8. | Lalloo F, Varley J, Moran A, et al.BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives[J].Eur J Cancer, 2006, 42(8):1143-1150. |
| 9. | Imkampe AK, Bates T.Impact of a raised body mass index on breast cancer survival in relation to age and disease extent at diagnosis[J].Breast J, 2010, 16(2):156-161. |
| 10. | Eng-Wong J, Orzano-Birgani J, Chow CK, et al.Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer[J].Cancer Epidemiol Biomarkers Prev, 2008, 17(7):1696-1701. |
| 11. | Samphao S, Wheeler AJ, Rafferty E, et al.Diagnosis of breast cancer in women age 40 and younger:delays in diagnosis result from underuse of genetic testing and breast imaging[J].Am J Surg, 2009, 198(4):538-543. |
| 12. | 华彬, 陆旭, 李波, 等.老年女性乳腺癌患者临床病理特点分析[J].中华老年医学杂志, 2013, 32(5):536-539. |
| 13. | Li J, Xing P, Feng L, et al.The value of substratified combined imaging assessment with mammography and ultrasonography for Chinese women with palpable breast masses[J].Breast Cancer Res Treat, 2014, 12.[Epub ahead of print]. |
| 14. | Saslow D, Boetes C, Burke W, et al.American cancer society guidelines for breast screening with MRI as an adjunct to mammography[J].CA Cancer J Clin, 2007, 57(2):75-89. |
| 15. | Adami HO, Malker B, Holmberg L, et al.The relation between survival and age at diagnosis and breast cancer[J].N Engl J Med, 1986, 315(9):559-563. |
| 16. | El Saghir NS, Seoud M, Khalil MK, et al.Effects of young age at presentation on survival in breast cancer[J].BMC Cancer, 2006, 6:194-201. |
| 17. | Lund MJ, Trivers KF, Porter PL, et al.Race and triple negative threats to breast cancer survival:a population-based study in Atlanta, GA[J].Breast Cancer Res Treat, 2009, 113(2):357-370. |
| 18. | Collins LC, Marotti JD, Gelber S, et al.Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer[J].Breast Cancer Res Treat, 2012, 131(3):1061-1066. |
| 19. | Margenthaler J.Younger women diagnosed with early-stage breast cancer more likely to die than older women[C].San Francisco, CA.American College of Surgeons Clinical Congress, October 12-16, 2008. |
| 20. | Chen S, Parmigiani G.Meta-analysis of BRCA1 and BRCA2 penetrance[J].J Clin Oncol, 2007, 25(11):1329-1333. |
| 21. | Evans DG, Moran A, Hartley R, et al.Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status[J].Br J Cancer, 2010, 102(7):1091-1098. |
| 22. | Lakhani SR, Van De Vijver MJ, Jacquemier J, et al.The pathology of familial breast cancer:predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2[J].J Clin Oncol, 2002, 20(9):2310-2318. |
| 23. | Lidereau R, Eisinger F, Champème MH, et al.Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer[J].Cancer Res, 2000, 60(5):1206-1210. |
| 24. | Nijenhuis MV, Rutgers EJ.Who should not undergo breast conservation[J].Breast, 2013, Suppl 2:S110-S114. |
| 25. | Voogd AC, Nielsen M, Peterse JL, et al.Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stageⅠandⅡbreast cancer:pooled results of two large European randomized trials[J].J Clin Oncol, 2001, 19(6):1688-1697. |
| 26. | Xiong Q, Valero V, Kau V, et al.Female patients with breast carcinoma age 30 years and younger have a poor prognosis:the M.D.Anderson Cancer Center experience[J].Cancer, 2001, 92(10):2523-2528. |
| 27. | Early Breast Cancer Trialists' Collaborative Group.Polychemotherapy for early breast cancer:an overview of the randomised trials[J].Lancet, 1998, 352(9132):930-942. |
| 28. | Levine MN, Bramwell VH, Pritchard KI, et al; National Cancer Institute of Canada Clinical Trials Group.Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer[J].J Clin Oncol, 1998, 16(8):2651-2658. |
| 29. | Mamounas EP, Bryant J, Lembersky B, et al.Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer:results from NSABP B-28[J].J Clin Oncol, 2005, 23(16):3686-3696. |
| 30. | Martin M, Pienkowski T, Mackey J, et al.Adjuvant docetaxel for node-positive breast cancer[J].N Engl J Med, 2005, 352(22):2302-2313. |
| 31. | Davies C, Pan H, Godwin J, et al.Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer:Atlas, a randomised trial[J].Lancet, 2013, 381(9869):805-816. |
| 32. | Goldhirsch A.Personalized adjuvant therapies:lessons from the past[J].Breast, 2013, Supp 2:S3-S7. |
| 33. | Jankowitz RC, Mcguire KP, Davidson NE.Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer[J].Breast, 2013, 22(Suppl 2):S165-S170. |
| 34. | Whelan TJ, Pignol JP, Levine MN, et al.Long-term results of hypofractionated radiation therapy for breast cancer[J].N Engl J Med, 2010, 362(6):513-520. |
| 35. | Smith BD, Arthur DW, Buchholz TA, et al.Accelerated partial breast irradiation consensus statement from the American society for radiation oncology (ASTRO)[J].J Am Coll Surg, 2009, 209(2):269-277. |
| 36. | Polgár C, Van Limbergen E, Pötter R, et al.Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery:recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009)[J].Radiother Oncol, 2010, 94(3):264-273. |
| 37. | Alshami HA, Kadasne AR, Khalfan M, et al.Pregnancy outcome in late maternal age in a high-income developing country[J].Arch Gynecol Obstet, 2011, 284(5):1113-1116. |
| 38. | Koyama H, Wada T, Nishizawa Y, et al.Cyclophosphamideinduced ovarian failure and its therapeutic significance in patients with breast cancer[J].Cancer, 1977, 39(4):1403-1409. |
| 39. | Sukumvanich P, Case LD, Van Zee K, et al.Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment:a prospective study[J].Cancer, 2010, 116(13):3102-3111. |
| 40. | Azim HA, Peccatori FA, Liptrott SJ, et al.Breast cancer and pregnancy:how safe is trastuzumab?[J].Nat Rev Clin Oncol, 2009, 6(6):367-370. |
| 41. | Pagani O, Partridge A, Korde L, et al.Pregnancy after breast cancer:if you wish, Ma'am[J].Breast Cancer Res Treat, 2011, 129(2):309-317. |
| 42. | Gerber B, von Minckwitz G, Stehle H, et al.Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy:the GBG 37 ZORO study[J].J Clin Oncol, 2011, 29(17):2334-2341. |
| 43. | Dittrich R, Lotz L, Keck G, et al.Live birth after ovarian tissue autotransplantation following overnight transportation before cryopreservation[J].Fertil Steril, 2012, 97(2):387-390. |
| 44. | Oktay K.Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation[J].J Clin Oncol, 2005, 23(16):3858-3859. |
| 45. | Picton HM, Harris SE, Muruvi W, et al.The in vitro growth and maturation of follicles[J].Reproduction, 2008, 136(6):703-715. |
| 46. | White YA, Woods DC, Takai Y, et al.Oocyte formation by mitotically active germ cells purified from ovaries of reproductive-age women[J].Nat Med, 2012, 18(3):413-421. |
| 47. | Anders CK, Johnson R, Litton J, et al.Breast cancer before age 40 years[J].Semin Oncol, 2009, 36(3):237-249. |
| 48. | Biffl WL, Myers A, Franciose RJ, et al.Is breast cancer in young Latinas a different disease?[J].Am J Surg, 2001, 182(6):596-600. |
| 49. | Foo CS, Su D, Chong CK, et al.Breast cancer in young Asian women:study on survival[J].Aust N Z J Surg, 2005, 75(7):566-572. |
| 50. | Lee KD, Chen SC, Chan CH, et al.Increased risk for second primary malignancies in women with breast cancer diagnosed at young age:a population-based study in Taiwan[J].Cancer Epidemiol Biomarkers Prev, 2008, 17(10):2647-2655. |
| 51. | Hooning MJ, Aleman BM, Hauptmann M, et al.Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer[J].J Clin Oncol, 2008, 26(34):5561-5568. |
- 1. Han W, Kim SW, Park IA, et al.Young age:an independent risk factor for disease-free survival in women with operable breast cancer[J].BMC Cancer, 2004, 4:82.
- 2. Han W, Kang SY; Korean Breast Cancer Society.Relationship between age at diagnosis and outcome of premenopausal breast cancer:age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer[J].Breast Cancer Res Treat, 2010, 119(1):193-200.
- 3. Kim EK, Noh WC, Han W, et al.Prognostic significance of young age ( < 35 years) by subtype based on ER, PR, and HER2 status in breast cancer:a nationwide registry-based study[J].World J Surg, 2011, 35(6):1244-1253.
- 4. Kim IK, Park S, Hwang H, et al.Clinical significance of age at the time of diagnosis among young breast cancer patients[J].J Breast Cancer, 2011, 14(4):314-321.
- 5. Althuis MD, Brogan DD, Coates RJ, et al.Breast cancers among very young premenopausal women (United States)[J].Cancer Causes Control, 2003, 14(2):151-160.
- 6. Rodriguez AO, Chew H, Cress R, et al.Evidence of poorer survival in pregnancy-associated breast cancer[J].Obstet Gynecol, 2008, 112(1):71-78.
- 7. Antoniou A, Pharoah PD, Narod S, et al.Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:a combined analysis of 22 studies[J].Am J Hum Genet, 2003, 72(5):1117-1130.
- 8. Lalloo F, Varley J, Moran A, et al.BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives[J].Eur J Cancer, 2006, 42(8):1143-1150.
- 9. Imkampe AK, Bates T.Impact of a raised body mass index on breast cancer survival in relation to age and disease extent at diagnosis[J].Breast J, 2010, 16(2):156-161.
- 10. Eng-Wong J, Orzano-Birgani J, Chow CK, et al.Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer[J].Cancer Epidemiol Biomarkers Prev, 2008, 17(7):1696-1701.
- 11. Samphao S, Wheeler AJ, Rafferty E, et al.Diagnosis of breast cancer in women age 40 and younger:delays in diagnosis result from underuse of genetic testing and breast imaging[J].Am J Surg, 2009, 198(4):538-543.
- 12. 华彬, 陆旭, 李波, 等.老年女性乳腺癌患者临床病理特点分析[J].中华老年医学杂志, 2013, 32(5):536-539.
- 13. Li J, Xing P, Feng L, et al.The value of substratified combined imaging assessment with mammography and ultrasonography for Chinese women with palpable breast masses[J].Breast Cancer Res Treat, 2014, 12.[Epub ahead of print].
- 14. Saslow D, Boetes C, Burke W, et al.American cancer society guidelines for breast screening with MRI as an adjunct to mammography[J].CA Cancer J Clin, 2007, 57(2):75-89.
- 15. Adami HO, Malker B, Holmberg L, et al.The relation between survival and age at diagnosis and breast cancer[J].N Engl J Med, 1986, 315(9):559-563.
- 16. El Saghir NS, Seoud M, Khalil MK, et al.Effects of young age at presentation on survival in breast cancer[J].BMC Cancer, 2006, 6:194-201.
- 17. Lund MJ, Trivers KF, Porter PL, et al.Race and triple negative threats to breast cancer survival:a population-based study in Atlanta, GA[J].Breast Cancer Res Treat, 2009, 113(2):357-370.
- 18. Collins LC, Marotti JD, Gelber S, et al.Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer[J].Breast Cancer Res Treat, 2012, 131(3):1061-1066.
- 19. Margenthaler J.Younger women diagnosed with early-stage breast cancer more likely to die than older women[C].San Francisco, CA.American College of Surgeons Clinical Congress, October 12-16, 2008.
- 20. Chen S, Parmigiani G.Meta-analysis of BRCA1 and BRCA2 penetrance[J].J Clin Oncol, 2007, 25(11):1329-1333.
- 21. Evans DG, Moran A, Hartley R, et al.Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status[J].Br J Cancer, 2010, 102(7):1091-1098.
- 22. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al.The pathology of familial breast cancer:predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2[J].J Clin Oncol, 2002, 20(9):2310-2318.
- 23. Lidereau R, Eisinger F, Champème MH, et al.Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer[J].Cancer Res, 2000, 60(5):1206-1210.
- 24. Nijenhuis MV, Rutgers EJ.Who should not undergo breast conservation[J].Breast, 2013, Suppl 2:S110-S114.
- 25. Voogd AC, Nielsen M, Peterse JL, et al.Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stageⅠandⅡbreast cancer:pooled results of two large European randomized trials[J].J Clin Oncol, 2001, 19(6):1688-1697.
- 26. Xiong Q, Valero V, Kau V, et al.Female patients with breast carcinoma age 30 years and younger have a poor prognosis:the M.D.Anderson Cancer Center experience[J].Cancer, 2001, 92(10):2523-2528.
- 27. Early Breast Cancer Trialists' Collaborative Group.Polychemotherapy for early breast cancer:an overview of the randomised trials[J].Lancet, 1998, 352(9132):930-942.
- 28. Levine MN, Bramwell VH, Pritchard KI, et al; National Cancer Institute of Canada Clinical Trials Group.Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer[J].J Clin Oncol, 1998, 16(8):2651-2658.
- 29. Mamounas EP, Bryant J, Lembersky B, et al.Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer:results from NSABP B-28[J].J Clin Oncol, 2005, 23(16):3686-3696.
- 30. Martin M, Pienkowski T, Mackey J, et al.Adjuvant docetaxel for node-positive breast cancer[J].N Engl J Med, 2005, 352(22):2302-2313.
- 31. Davies C, Pan H, Godwin J, et al.Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer:Atlas, a randomised trial[J].Lancet, 2013, 381(9869):805-816.
- 32. Goldhirsch A.Personalized adjuvant therapies:lessons from the past[J].Breast, 2013, Supp 2:S3-S7.
- 33. Jankowitz RC, Mcguire KP, Davidson NE.Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer[J].Breast, 2013, 22(Suppl 2):S165-S170.
- 34. Whelan TJ, Pignol JP, Levine MN, et al.Long-term results of hypofractionated radiation therapy for breast cancer[J].N Engl J Med, 2010, 362(6):513-520.
- 35. Smith BD, Arthur DW, Buchholz TA, et al.Accelerated partial breast irradiation consensus statement from the American society for radiation oncology (ASTRO)[J].J Am Coll Surg, 2009, 209(2):269-277.
- 36. Polgár C, Van Limbergen E, Pötter R, et al.Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery:recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009)[J].Radiother Oncol, 2010, 94(3):264-273.
- 37. Alshami HA, Kadasne AR, Khalfan M, et al.Pregnancy outcome in late maternal age in a high-income developing country[J].Arch Gynecol Obstet, 2011, 284(5):1113-1116.
- 38. Koyama H, Wada T, Nishizawa Y, et al.Cyclophosphamideinduced ovarian failure and its therapeutic significance in patients with breast cancer[J].Cancer, 1977, 39(4):1403-1409.
- 39. Sukumvanich P, Case LD, Van Zee K, et al.Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment:a prospective study[J].Cancer, 2010, 116(13):3102-3111.
- 40. Azim HA, Peccatori FA, Liptrott SJ, et al.Breast cancer and pregnancy:how safe is trastuzumab?[J].Nat Rev Clin Oncol, 2009, 6(6):367-370.
- 41. Pagani O, Partridge A, Korde L, et al.Pregnancy after breast cancer:if you wish, Ma'am[J].Breast Cancer Res Treat, 2011, 129(2):309-317.
- 42. Gerber B, von Minckwitz G, Stehle H, et al.Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy:the GBG 37 ZORO study[J].J Clin Oncol, 2011, 29(17):2334-2341.
- 43. Dittrich R, Lotz L, Keck G, et al.Live birth after ovarian tissue autotransplantation following overnight transportation before cryopreservation[J].Fertil Steril, 2012, 97(2):387-390.
- 44. Oktay K.Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation[J].J Clin Oncol, 2005, 23(16):3858-3859.
- 45. Picton HM, Harris SE, Muruvi W, et al.The in vitro growth and maturation of follicles[J].Reproduction, 2008, 136(6):703-715.
- 46. White YA, Woods DC, Takai Y, et al.Oocyte formation by mitotically active germ cells purified from ovaries of reproductive-age women[J].Nat Med, 2012, 18(3):413-421.
- 47. Anders CK, Johnson R, Litton J, et al.Breast cancer before age 40 years[J].Semin Oncol, 2009, 36(3):237-249.
- 48. Biffl WL, Myers A, Franciose RJ, et al.Is breast cancer in young Latinas a different disease?[J].Am J Surg, 2001, 182(6):596-600.
- 49. Foo CS, Su D, Chong CK, et al.Breast cancer in young Asian women:study on survival[J].Aust N Z J Surg, 2005, 75(7):566-572.
- 50. Lee KD, Chen SC, Chan CH, et al.Increased risk for second primary malignancies in women with breast cancer diagnosed at young age:a population-based study in Taiwan[J].Cancer Epidemiol Biomarkers Prev, 2008, 17(10):2647-2655.
- 51. Hooning MJ, Aleman BM, Hauptmann M, et al.Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer[J].J Clin Oncol, 2008, 26(34):5561-5568.